Genomewide Association Study of Simvastatin Pharmacokinetics.

Cytochrome P-450 CYP3A / genetics Genotype Humans Liver-Specific Organic Anion Transporter 1 / genetics Organic Anion Transporters / genetics Polymorphism, Single Nucleotide Prospective Studies Retrospective Studies Simvastatin / pharmacokinetics

Journal

Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741

Informations de publication

Date de publication:
09 2022
Historique:
received: 01 04 2022
accepted: 17 05 2022
pubmed: 3 6 2022
medline: 24 8 2022
entrez: 2 6 2022
Statut: ppublish

Résumé

We investigated genetic determinants of single-dose simvastatin pharmacokinetics in a prospective study of 170 subjects and a retrospective cohort of 59 healthy volunteers. In a microarray-based genomewide association study with the prospective data, the SLCO1B1 c.521T>C (p.Val174Ala, rs4149056) single nucleotide variation showed the strongest, genomewide significant association with the area under the plasma simvastatin acid concentration-time curve (AUC; P = 6.0 × 10

Identifiants

DOI: 10.1002/cpt.2674 PMID: 35652242 PMC: PMC9540481
pubmed: 35652242
doi: 10.1002/cpt.2674
pmc: PMC9540481
doi:

Substances chimiques

Liver-Specific Organic Anion Transporter 1 0
Organic Anion Transporters 0
SLCO1B1 protein, human 0
Simvastatin AGG2FN16EV
Cytochrome P-450 CYP3A EC 1.14.14.1
CYP3A4 protein, human EC 1.14.14.55

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

676-686

Informations de copyright

© 2022 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.

Références

Clin Pharmacol Ther. 2000 Jan;67(1):48-56
pubmed: 10668853
Clin Pharmacol Ther. 2021 Mar;109(3):646-657
pubmed: 32961594
Pharmacogenomics. 2017 Apr;18(5):459-469
pubmed: 28350522
Pharmacogenet Genomics. 2014 Oct;24(10):486-91
pubmed: 25051018
Am J Hum Genet. 2001 Apr;68(4):978-89
pubmed: 11254454
Clin Pharmacol Ther. 1998 Mar;63(3):332-41
pubmed: 9542477
Clin Pharmacol Ther. 2019 Jun;105(6):1345-1361
pubmed: 30916389
Drug Des Devel Ther. 2017 Dec 07;11:3503-3510
pubmed: 29263648
Genome Med. 2013 Jan 11;5(1):1
pubmed: 23311897
Pharmacogenet Genomics. 2006 Dec;16(12):873-9
pubmed: 17108811
Genome Res. 2012 Jan;22(1):1-8
pubmed: 22147369
Drug Metab Dispos. 2021 Sep;49(9):750-759
pubmed: 34162690
J Biol Chem. 2001 Sep 21;276(38):35669-75
pubmed: 11477075
Clin Pharmacol Ther. 2021 Dec;110(6):1622-1632
pubmed: 34580865
Basic Clin Pharmacol Toxicol. 2018 Apr;122(4):383-387
pubmed: 29117640
Clin Pharmacol Ther. 2022 May;111(5):1007-1021
pubmed: 35152405
Bull Exp Biol Med. 2006 Jun;141(6):701-3
pubmed: 17364054
Pharmacogenomics. 2008 Sep;9(9):1217-27
pubmed: 18781850
Drug Des Devel Ther. 2020 Nov 24;14:5129-5141
pubmed: 33262574
Chem Res Toxicol. 2020 Jan 21;33(1):172-180
pubmed: 31560202
Chem Res Toxicol. 2021 Jan 18;34(1):103-109
pubmed: 33393779
Drug Metab Dispos. 2021 Aug;49(8):658-667
pubmed: 34045219
Clin Pharmacol Ther. 2018 Mar;103(3):399-401
pubmed: 29134625
Clin Pharmacol Ther. 2019 Jan;105(1):29-32
pubmed: 30536702
N Engl J Med. 2008 Aug 21;359(8):789-99
pubmed: 18650507
Drug Metab Dispos. 2002 May;30(5):505-12
pubmed: 11950779
ACR Open Rheumatol. 2019 Mar 15;1(1):58-62
pubmed: 31777781
Pharmacogenomics. 2009 Nov;10(11):1743-51
pubmed: 19891551
Pharmacogenomics. 2008 Jan;9(1):19-33
pubmed: 18154446
Pharmacol Rev. 2011 Mar;63(1):157-81
pubmed: 21245207
Pharmacogenomics. 2009 Oct;10(10):1617-24
pubmed: 19842935
Drug Metab Dispos. 2008 Nov;36(11):2287-91
pubmed: 18669585
Pharm Res. 2004 Sep;21(9):1686-91
pubmed: 15497697
Clin Pharmacol Ther. 2006 Dec;80(6):565-81
pubmed: 17178259
Pharmacogenomics J. 2011 Aug;11(4):274-86
pubmed: 20386561
Drug Metab Dispos. 2011 Apr;39(4):724-8
pubmed: 21212239
J Cardiovasc Pharmacol. 2015 Jul;66(1):80-5
pubmed: 26164721
Chem Biol Interact. 2021 Aug 25;345:109559
pubmed: 34153224
Clin Pharmacol Ther. 2019 Sep;106(3):668-680
pubmed: 30989645
Br J Clin Pharmacol. 2003 Jul;56(1):120-4
pubmed: 12848784
Clin Pharmacol Ther. 2008 Oct;84(4):457-61
pubmed: 19238649
Chem Res Toxicol. 2019 Aug 19;32(8):1583-1590
pubmed: 31293154
Eur J Clin Pharmacol. 2019 Sep;75(9):1227-1235
pubmed: 31172248
Clin Pharmacol Ther. 2017 Oct;102(4):688-700
pubmed: 28378927
Chem Biol Interact. 2021 Dec 1;350:109700
pubmed: 34648813
J Am Coll Cardiol. 2009 Oct 20;54(17):1609-16
pubmed: 19833260
Drug Metab Dispos. 2005 Apr;33(4):537-46
pubmed: 15616150
Clin Pharmacol Ther. 2012 Jul;92(1):112-7
pubmed: 22617227
Am J Hum Genet. 2003 Nov;73(5):1162-9
pubmed: 14574645
Pharmacogenet Genomics. 2016 Jan;26(1):40-3
pubmed: 26488616

Auteurs

Anssi J H Mykkänen (AJH)

Department of Clinical Pharmacology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Individualized Drug Therapy Research Program, University of Helsinki, Helsinki, Finland.
ORCID: 0000-0003-3348-1325

Suvi Taskinen (S)

Department of Clinical Pharmacology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Individualized Drug Therapy Research Program, University of Helsinki, Helsinki, Finland.

Mikko Neuvonen (M)

Department of Clinical Pharmacology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Individualized Drug Therapy Research Program, University of Helsinki, Helsinki, Finland.

Maria Paile-Hyvärinen (M)

Department of Clinical Pharmacology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Individualized Drug Therapy Research Program, University of Helsinki, Helsinki, Finland.

E Katriina Tarkiainen (EK)

Department of Clinical Pharmacology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Individualized Drug Therapy Research Program, University of Helsinki, Helsinki, Finland.

Tuomas Lilius (T)

Department of Clinical Pharmacology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Individualized Drug Therapy Research Program, University of Helsinki, Helsinki, Finland.
ORCID: 0000-0002-8361-3683

Tuija Tapaninen (T)

Department of Clinical Pharmacology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Individualized Drug Therapy Research Program, University of Helsinki, Helsinki, Finland.
ORCID: 0000-0003-4562-9606

Janne T Backman (JT)

Department of Clinical Pharmacology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Individualized Drug Therapy Research Program, University of Helsinki, Helsinki, Finland.
ORCID: 0000-0002-9577-2788

Aleksi Tornio (A)

Department of Clinical Pharmacology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Individualized Drug Therapy Research Program, University of Helsinki, Helsinki, Finland.
ORCID: 0000-0001-5713-5692

Mikko Niemi (M)

Department of Clinical Pharmacology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Individualized Drug Therapy Research Program, University of Helsinki, Helsinki, Finland.
ORCID: 0000-0003-4550-2189

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Hémoprotéines › Cytochromes › Cytochrome P-450 enzyme system › Famille-3 de cytochromes P450 › Cytochrome P-450 CYP3A › Genomewide Association Study of Simvastatin...
questionsmedicales.fr › Phénomènes génétiques › Génotype › Genomewide Association Study of Simvastatin...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Genomewide Association Study of Simvastatin...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Protéines de transport membranaire › Protéines transporteurs de solutés › Polypeptide C de transport d'anions organiques › Genomewide Association Study of Simvastatin...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Protéines de transport membranaire › Pompes ioniques › Transporteurs d'anions › Transporteurs d'anions organiques › Genomewide Association Study of Simvastatin...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Polymorphisme génétique › Polymorphisme de nucléotide simple › Genomewide Association Study of Simvastatin...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Genomewide Association Study of Simvastatin...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Genomewide Association Study of Simvastatin...
questionsmedicales.fr › Composés polycycliques › Hydrocarbures aromatiques polycycliques › Naphtalènes › Lovastatine › Simvastatine › Genomewide Association Study of Simvastatin...